BeiGene (BGNE)
(Delayed Data from NSDQ)
$160.77 USD
-1.40 (-0.86%)
Updated May 14, 2024 04:00 PM ET
After-Market: $160.79 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
BGNE 160.77 -1.40(-0.86%)
Will BGNE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BGNE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BGNE
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
BGNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Top 5 Momentum Picks for January After a Fabulous 2023
New Strong Buy Stocks for December 22nd
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
Other News for BGNE
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
Leap Therapeutics: The DisTinGuish Trial Provides A Near-Term Catalyst
Merck discontinues testing of experimental skin cancer combo therapy
Buy Rating Affirmed for BeiGene on Strong Q4 Performance and Promising Brukinsa Sales
BeiGene’s Soaring Sales and Path to Profitability Reinforce Buy Rating